Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Edition
European
US
Dermatology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Dermatitis Artefacta Treatment
9
Mins
June 2024
Dermatitis artefacta (DA), also known as artefactual skin disease, is a rare psychocutaneous disorder characterised by…
Read more
10
Mins
22nd October 2021
Patient-Reported Outcomes with Monoclonal Antibody Therapies in Patients with Moderate-to-Severe Plaque Psoriasis
Richard B. Warren highlighted Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the Phase III BE VIVID trial in patients…
10
Mins
20th October 2021
Efficacy and Safety of Monoclonal Antibody Therapies in Patients with Moderate-to-Severe Plaque Psoriasis
In the late-breaking research sessions, Reich presented BE RADIANT, the first Phase III trial to compare inhibition of IL-17A and IL-17F…
6
Mins
15th October 2021
Where Do We Begin? The Key Role of the IL-23 Pathway in Psoriasis and Psoriatic Arthritis
This Janssen-sponsored live satellite symposium, entitled ‘Where do we begin? The key role of the IL-23 pathway in psoriasis and psoriatic…
9
Mins
17th June 2021
Pioneering Best Practices in Atopic Dermatitis: Results from the Quality of Care Initiative
Pioneering global best practices in atopic dermatitis (AD) and implementing them in the clinic are important steps towards optimising patient care…
11
Mins
17th May 2021
Botulinum Toxins in Medical and Cosmetic Dermatology
Botulinum neurotoxins (BoNTs) are derived from Clostridium botulinum, a gram-positive anaerobe. While there are seven subtypes of BoNT (A to G), only A…
5
Mins
3rd May 2021
Prominent Cutaneous Manifestation of COVID-19: A Case Report
The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen and the subsequent coronavirus disease (COVID-19) mainly affect the lung…
10
Mins
29th March 2021
Advancing Breakthrough Innovative Treatment in Paediatric Dermatitis and Various Skin Disorders
Eczematous dermatitis (or eczema) includes AD, CD, and DD. This inflammatory skin reaction presents as erythema, vesicles, desquamation…
15
Mins
23rd March 2021
The Treatment Landscape of Atopic Dermatitis: Interviews with Three Consultant Dermatologists
Atopic dermatitis (AD), sometimes referred to as ‘atopic eczema’, is a common, chronic, pruritic, Type II inflammatory skin disease which is associated…
Loading posts...
« Previous
1
…
5
6
7
8
9
…
25
Next »